Youtor
What Is Congenital Adrenal Hyperplasia CAH
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=e8BHPmUZVko
Congenital Adrenal Hyperplasia (CAH) is a chronic and potentially life-threatening rare genetic disorder characterized by an inability to produce cortisol, and, in many CAH patients, an inability to produce aldosterone. Due to the severity of the disease, most developed countries have established newborn screening programs to test for Classic CAH at birth. There are approximately 20,000 – 30,000 classic CAH patients in the U.S. and 50,000 in the EU. There have been no meaningful improvements in CAH treatments in approximately 50 years. • Spruce Biosciences is conducting two late-stage clinical trials evaluating its wholly-owned investigational product candidate, tildacerfont, a CRF1 receptor antagonist, for the treatment of adults with Classic Congenital Adrenal Hyperplasia (CAH). The CAHmelia clinical trials evaluating tildacerfont in adults with Classic CAH are open for screening. To learn more, see if you may qualify and view trial locations, please visit www.clarahealth.com/studies/cahmelia. For more information on the ongoing trials in adult patients with Classic CAH, please visit www.clinicaltrials.gov. • #CongenitalAdrenalHyperplasia #clinicaltrials #CAH #EndocrineDisorders #tildacerfont #SpruceBiosciences #CAHmelia • About Spruce Biosciences • Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from Classic Congenital Adrenal Hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of Polycystic Ovary Syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States). To learn more, visit www.sprucebiosciences.com. • Twitter: / spruce_bio • LinkedIn: / spruce-biosciences • Facebook: / sprucebio • Disclaimer: Tildacerfont is an investigational product and has not been approved for commercial use in the United States or any other country for any indication. Learn more at www.clinicaltrials.gov using the identifier NCT04544410 and NCT04457336.
#############################
